![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VGLL1 |
Gene summary for VGLL1 |
![]() |
Gene information | Species | Human | Gene symbol | VGLL1 | Gene ID | 51442 |
Gene name | vestigial like family member 1 | |
Gene Alias | TDU | |
Cytomap | Xq26.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q99990 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51442 | VGLL1 | P8T-E | Human | Esophagus | ESCC | 3.88e-09 | 3.19e-01 | 0.0889 |
51442 | VGLL1 | P39T-E | Human | Esophagus | ESCC | 3.60e-13 | 5.82e-01 | 0.0894 |
51442 | VGLL1 | P74T-E | Human | Esophagus | ESCC | 1.96e-03 | 2.21e-01 | 0.1479 |
51442 | VGLL1 | P82T-E | Human | Esophagus | ESCC | 1.13e-10 | 9.94e-01 | 0.1072 |
51442 | VGLL1 | P84T-E | Human | Esophagus | ESCC | 8.33e-03 | 4.18e-01 | 0.0933 |
51442 | VGLL1 | P127T-E | Human | Esophagus | ESCC | 8.31e-06 | 2.35e-01 | 0.0826 |
51442 | VGLL1 | P130T-E | Human | Esophagus | ESCC | 8.96e-45 | 1.14e+00 | 0.1676 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VGLL1 | SNV | Missense_Mutation | c.223N>T | p.Met75Leu | p.M75L | Q99990 | protein_coding | tolerated(0.1) | benign(0.009) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
VGLL1 | SNV | Missense_Mutation | novel | c.12G>A | p.Met4Ile | p.M4I | Q99990 | protein_coding | tolerated(0.21) | benign(0.015) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
VGLL1 | SNV | Missense_Mutation | c.370T>A | p.Ser124Thr | p.S124T | Q99990 | protein_coding | tolerated(0.13) | benign(0.024) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
VGLL1 | SNV | Missense_Mutation | c.493N>T | p.Arg165Cys | p.R165C | Q99990 | protein_coding | tolerated(0.25) | benign(0) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
VGLL1 | SNV | Missense_Mutation | c.639N>T | p.Lys213Asn | p.K213N | Q99990 | protein_coding | deleterious(0) | possibly_damaging(0.539) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
VGLL1 | SNV | Missense_Mutation | c.312G>C | p.Leu104Phe | p.L104F | Q99990 | protein_coding | tolerated(0.06) | benign(0.049) | TCGA-CM-6677-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VGLL1 | SNV | Missense_Mutation | rs370153819 | c.77N>A | p.Arg26Gln | p.R26Q | Q99990 | protein_coding | tolerated(0.4) | benign(0.119) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
VGLL1 | SNV | Missense_Mutation | c.292C>T | p.Arg98Cys | p.R98C | Q99990 | protein_coding | tolerated(0.06) | benign(0.27) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
VGLL1 | SNV | Missense_Mutation | novel | c.763C>A | p.Leu255Met | p.L255M | Q99990 | protein_coding | tolerated_low_confidence(0.3) | benign(0.271) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VGLL1 | SNV | Missense_Mutation | novel | c.281C>A | p.Pro94His | p.P94H | Q99990 | protein_coding | deleterious(0) | benign(0.187) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |